Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objectives: Information on the recently COVID‐19‐associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID‐19), and review the published literature from Western countries. Methods: Prospective study (March to May, 2020) that included all COVID‐19 patients admitted to a tertiary hospital. Modified AspICU and European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria were used. Results: COVID‐19‐associated pulmonary aspergillosis was diagnosed in eight patients (3.3% of 239 ICU patients), mostly affected non‐immunocompromised patients (75%) with severe acute respiratory distress syndrome (ARDS) receiving corticosteroids. Diagnosis was established after a median of 15 days under mechanical ventilation. Bronchoalveolar lavage was performed in two patients with positive Aspergillus fumigatus cultures and galactomannan (GM) index. Serum GM was positive in 4/8 (50%). Thoracic CT scan findings fulfilled EORTC/MSG criteria in one case. Isavuconazole was used in 4/8 cases. CAPA‐related mortality was 100% (8/8). Compared with colonised patients, CAPA subjects were administered tocilizumab more often (100% vs. 40%, p = .04), underwent longer courses of antibacterial therapy (13 vs. 5 days, p = .008), and had a higher all‐cause mortality (100% vs. 40%, p = .04). We reviewed 96 similar cases from recent publications: 59 probable CAPA (also putative according modified AspICU), 56 putative cases and 13 colonisations according AspICU algorithm; according EORTC/MSG six proven and two probable. Overall, mortality in the reviewed series was 56.3%. Conclusions: COVID‐19‐associated pulmonary aspergillosis must be considered a serious and potentially life‐threatening complication in patients with severe COVID‐19 receiving immunosuppressive treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
COVID-19 Associated Pulmonary Aspergillosis
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses · doi:10.1111/myc.13096 · Cited by 547 · cited 6×
“#2 52/M Obesity Severe (93 mmHg) Yes (8) Yes (7) No No Ceftriaxone Piperacillin/tazobactam Linezolid LPV/r Hydroxychloroquine IFN-B1b Not performed N/C Putative Putative BAS: A.”
BackgroundInfluentialDiagnosing COVID-19-associated pulmonary aspergillosis
Verweij, P. E., Gangneux, J.-P., Bassetti, M., Brüggemann, R. J. M., Cornely, O. A., Koehler, P., Lass-Flörl, C., van de Veerdonk, F. L., Chakrabarti, A., & Hoenigl, M. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30027-6 · Cited by 181
Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient
Blaize, M., Mayaux, J., Nabet, C., Lampros, A., Marcelin, A.-G., Thellier, M., Piarroux, R., Demoule, A., & Fekkar, A. (2020) · Emerging infectious diseases · doi:10.3201/eid2607.201603 · Cited by 142
Intensive care management of influenza-associated pulmonary aspergillosis
Koehler, P., Bassetti, M., Kochanek, M., Shimabukuro-Vornhagen, A., & Cornely, O. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.031 · Cited by 82
Cited by
Gangneux, J.-P., Dannaoui, E., Fekkar, A., Luyt, C.-E., Botterel, F., De Prost, N., Tadié, J.-M., Reizine, F., Houzé, S., Timsit, J.-F., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00442-2 · Cited by 284
Machado, M., Estévez, A., Sánchez-Carrillo, C., Guinea, J., Escribano, P., Alonso, R., Valerio, M., Padilla, B., Bouza, E., & Muñoz, P. (2022) · Journal of Fungi · doi:10.3390/jof8030305 · Cited by 53
Self-citation
Metadata
- Authors
- Machado, M., Valerio, M., Álvarez‐Uría, A., Olmedo, M., Veintimilla, C., Padilla, B., De la Villa, S., Guinea, J., Escribano, P., Ruiz‐Serrano, M. J., Reigadas, E., Alonso, R., Guerrero, J. E., Hortal, J., Bouza, E., Muñoz, P., & the COVID‐19 Study Group
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2020-11-29
- Volume
- 64
- Issue
- 2
- Pages
- 132-143
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W3099019571
- Cited by
- 203
- References
- 5
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity. https://app.cochat.ai/papers/10.1111/myc.13213
- The paper
- Machado, M., Valerio, M., Álvarez‐Uría, A., Olmedo, M., Veintimilla, C., Padilla, B., De la Villa, S., Guinea, J., Escribano, P., Ruiz‐Serrano, M. J., Reigadas, E., Alonso, R., Guerrero, J. E., Hortal, J., Bouza, E., Muñoz, P., & the COVID‐19 Study Group. (2021). Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity. Mycoses. https://doi.org/10.1111/myc.13213
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.